Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma
NCT05170789
Withdrawn
The food and drug administration (FDA) has approved the use of Selinexor, an oral, first-in class, exportin 1 (XPO1) inhibitor, in combination with low-dose dexamethasone in patients with triple-refractory (disease refractory to proteasome inhibitors (PI), immunomodulatory imid agents (IMiD), and anti-Cluster of Differentiation 38 (CD38) monoclonal antibodies (mAb)), or relapsed refractory multiple myeloma (RRMM). SLAMF7 (human Signaling Lymphocyte Activation Molecule Family 7) is a receptor tha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2022
Locations: Tulane Cancer Center, New Orleans, Louisiana
Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
NCT01849783
Completed
This phase II trial investigates whether patients greater than or equal to 65 years of age diagnosed with myeloma or another plasma cell malignancy will have better outcomes with transplant followed by maintenance therapy, as primarily measured by progression-free survival, versus non-transplant approaches.
Gender:
ALL
Ages:
Between 65 years and 85 years
Trial Updated:
04/17/2022
Locations: University of Iowa Hospitals and Clinics, Iowa City, Iowa
Conditions: Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Primary Systemic Amyloidosis, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Register for Updates
Duration of Analgesia After Popliteal Fossa Nerve Blockade: Effects of Dexamethasone and Buprenorphine
NCT01277159
Completed
Patients scheduled to go home after ankle surgery at HSS typically receive a sciatic nerve block in the popliteal fossa and oral analgesic tablets (such as Percocet). Popliteal fossa nerve blockade has reduced pain for these patients (YaDeau et al, Anesth Analg 2008;106:1916-20), but unfortunately the patients still often experience moderate to severe pain after the block wears off. The investigators wish to study two additives that may prolong the period of analgesia provided by the nerve block... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/12/2022
Locations: Hospital for Special Surgery, New York, New York
Conditions: Patients Undergoing Ankle Surgery
Register for Updates
Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease
NCT04413279
Completed
To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in evaporative dry eye disease (DED) patients with meibomian gland disfunction (MGD) and underlying inflammation undergoing LipiFlow Thermal Pulsation.
Gender:
ALL
Ages:
All
Trial Updated:
04/11/2022
Locations: Eye Surgeons of Indiana, Indianapolis, Indiana
Conditions: Dry Eye Syndromes
Register for Updates
Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease
NCT04413253
Terminated
To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in patients with dry eye who are beginning treatment with Xiidra (lifitegrast ophthalmic solution) to reduce the signs and symptoms of dry eye disease.
Gender:
ALL
Ages:
All
Trial Updated:
04/11/2022
Locations: Eye Surgeons of Indiana, Indianapolis, Indiana
Conditions: Dry Eye Syndromes
Register for Updates
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
NCT02471911
Completed
This study evaluates the addition of selinexor (KPT-330) to RICE chemotherapy in the treatment of relapsed and refractory aggressive B-Cell Lymphoma, with the goal of improved response rates (as compared to RICE chemotherapy alone).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2022
Locations: Weill Cornell Medical College, New York, New York
Conditions: Diffuse Large B-Cell Lymphoma
Register for Updates
DEXTENZA Therapy for Treatment of Allergic Conjunctivitis
NCT04708821
Completed
This prospective, open-label, single-center, randomized, investigator-sponsored clinical study seeks to compare patient-reported and clinical outcomes with DEXTENZA versus topical steroid or antihistamine treatment in patients with allergic conjunctivitis
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/06/2022
Locations: Clinical Research Center of Florida, Pompano Beach, Florida
Conditions: Bilateral Conjunctivitis (Disorder)
Register for Updates
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
NCT00061945
Completed
This phase I/II trial studies the side effects and best dose of alemtuzumab when given together with combination chemotherapy and to see how well it works in treating patients with untreated acute lymphoblastic leukemia. Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy also work in diffe... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
04/05/2022
Locations: Cancer and Leukemia Group B, Chicago, Illinois
Conditions: Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, L1 Adult Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Adult Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Register for Updates
Dextenza in Pterygium Surgery
NCT04403516
Completed
DEXTENZA for the treatment of post-surgical pain and inflammation compared to standard of care topical prednisolone acetate 1% in patients who undergo pterygium surgery (excision of pterygium with conjunctival autograft)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2022
Locations: New York Eye Specialists, New York, New York
Conditions: Pterygium
Register for Updates
Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy
NCT03532022
Withdrawn
This study is an open-label, randomised, titration-blinded, parallel arm, multicenter study to compare twice daily Chronocort® with standard care in participants with Congenital Adrenal Hyperplasia (CAH). This study will be conducted in the USA.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
03/31/2022
Locations: Diabetes and Endocrinology Consultants PC, Morehead City, North Carolina
Conditions: Congenital Adrenal Hyperplasia
Register for Updates
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
NCT00290511
Completed
The goal of this clinical research study is to learn if chemotherapy given with rituximab, followed by Ibritumomab tiuxetan (Zevalin), and then followed by rituximab can help to control lymphoma. The safety of this treatment schedule will also be studied. Objectives: 1. To assess whether the time to progression for these high-risk patients can be prolonged to a median of 36 months, compared to the historical expectation of approximately 24 months. 2. To assess the tolerance and efficacy of Y2B... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
03/24/2022
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531
NCT01813227
Completed
The purpose of this study is to evaluate the safety and effectiveness of an investigational study drug called carfilzomib. The investigators want to find out what effects, good and/or bad, it has on patients and their cancer if treatment continues beyond previous carfilzomib treatment study. Carfilzomib (KyprolisTM) is approved by the U.S. Food and Drug Administration (FDA) to be used only in certain U.S. patients with relapsed and refractory multiple myeloma that have tried and failed other th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2022
Locations: John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Waldenstrom Macroglobulinemia
Register for Updates